 | |
| Clinical data | |
|---|---|
| Other names | LY-404,187;N-2-[4-(4-cyanophenyl)phenyl]propyl-2-propanesulfonamide |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H22N2O2S |
| Molar mass | 342.46 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
LY-404187 is anAMPA receptorpositive allosteric modulator which was developed byEli Lilly and Company.[1] It is a member of thebiarylpropylsulfonamide class of AMPA receptor potentiators.[2]
LY-404187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggestingantidepressant action as well as having possible application in the treatment ofschizophrenia,Parkinson's disease andADHD. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels ofBDNF in the brain.[3] It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.[4][5]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
